Recently, several EZH2 inhibitors have exhibited promising therapeutic effects in GC-derived B-cell lymphoma patients bearing EZH2-activating mutations [13,14]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.